HYPERION DEFI INC (HYPD) Stock Price, Forecast & Analysis
NASDAQ:HYPD • US30234E2037
HYPD Key Statistics, Chart & Performance
The current stock price of HYPD is 4.14 USD. In the past month the price increased by 23.58%.
HYPD Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HYPD.
HYPD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HYPD. HYPD may be in some trouble as it scores bad on both profitability and health.
HYPD Financial Highlights
Over the last trailing twelve months HYPD reported a non-GAAP Earnings per Share(EPS) of -50.93. The EPS increased by 4.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.17% | ||
| ROE | -70.41% | ||
| Debt/Equity | 0.11 |
HYPD Forecast & Estimates
8 analysts have analysed HYPD and the average price target is 5.99 USD. This implies a price increase of 44.75% is expected in the next year compared to the current price of 4.14.
For the next year, analysts expect an EPS growth of 82.74% and a revenue growth -7.67% for HYPD
HYPD Ownership
HYPD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HYPD
Company Profile
Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
Company Info
HYPERION DEFI INC
295 Madison Avenue, Suite 2400
New York City NEW YORK US
Employees: 13
Phone: 18333936684
HYPERION DEFI INC / HYPD FAQ
What does HYPD do?
Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
Can you provide the latest stock price for HYPERION DEFI INC?
The current stock price of HYPD is 4.14 USD. The price increased by 7.25% in the last trading session.
What is the dividend status of HYPERION DEFI INC?
HYPD does not pay a dividend.
What is the ChartMill rating of HYPERION DEFI INC stock?
HYPD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is HYPERION DEFI INC (HYPD) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HYPD.
What is the market capitalization of HYPD stock?
HYPERION DEFI INC (HYPD) has a market capitalization of 35.07M USD. This makes HYPD a Nano Cap stock.
Can you provide the ownership details for HYPD stock?
You can find the ownership structure of HYPERION DEFI INC (HYPD) on the Ownership tab.